Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

mucositis-stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis (86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia (65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation (35%/30%) and vomiting (29%/23%). The most common adverse events seen in patients with carcinomas of the head and neck receiving ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia (45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%), and headache (14%/26%).

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual resu
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/23/2014)... CORALVILLE, Iowa , Sept. 23, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... received a No Objection Letter (NOL) from Health ... Canada for its lead product candidate ... hydrocodone prodrug in development for acute moderate to ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... 23, 2014  Medela announced today that it has ... assigning Medela as the exclusive distributor of the ABC ... Medela Enteral Feeding Pump. Through this agreement, Medela will ... and healthcare professionals by offering a comprehensive set of ... Pump is integral to the delivery of human milk ...
Breaking Medicine Technology:KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2
... 14, 2011 Novocure, a commercial stage private ... former senior OSI Pharmaceuticals executives to its Global ... for bringing the company,s new tumor treating fields ... Peter M. Melnyk has joined Novocure as ...
...  SRI International has been awarded a contract worth up ... Institute of Allergy and Infectious Diseases (NIAID), part of ... will allow SRI to continue a program that supports ... the translation of basic research into clinical applications. Since ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 2SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 3
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 23, 2014 What information do ... National Quality Forum (NQF) released a report ( ... and an infographic ( http://bit.ly/1tX3lzA ) resulting from ... healthcare, how patients define affordability, and what information ... the best possible healthcare at the lowest possible ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... obese as teenagers could grow up to earn up ... weight. So says Petter Lundborg of Lund University, Paul ... University and Lund University, all in Sweden. The team ... the United States, and the results are published in ... analyzed large-scale data of 145,193 Swedish-born brothers who enlisted ...
Breaking Medicine News(10 mins):Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2
... A path breaking research published today seems to have ... be able to manufacture their own sperms. Lesbian couples// ... ,Researchers have applied for permission to generate synthetic ... this move will be ethical is a question that ...
... the key to not only stopping heart attacks in ... Researchers at Mount Sinai School of Medicine have shown ... novel contrast agent know as N1177 can detect dangerous, ... findings may help physicians diagnosis a heart attack before ...
... Alirajpur in Jhabua district, beat his wife to death. Reason? ... another young man killed his brother with an arrow when ... owned by him. ,Often the reasons for murders ... entering the neighbour's territory or someone's refusal to lend a ...
... - If you are obese, blame it on your gene. A ... called FTO portray mutation in both their copies, then such people ... people who possess normal copies of the gene. ,Researchers ... of what is happening, this research could give us an answer ...
... M.D., director of the Yale Child Study Center and ... discuss the expansion of the Center’s specialty clinical services ... at Greenwich Library, 101 W. Putnam Ave., Greenwich. ... new clinical services, which will also benefit clients from ...
... Northeastern states in the US are stepping up their efforts ... mercury emissions.// ,Throughout the Northeast, mercury contamination ... that occurs naturally. , It is released ... generating plants. ,Smokestack emissions drift across state ...
Cached Medicine News:Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 3Health News:Efforts Underway to Fight Alcoholism Among Tribals 4Health News:US States Get Ready to Fight Mercury Pollution 2